Propanc Biopharma, Inc. - Common Stock (PPCB)
Healthcare › Pharmaceutical Preparations
Investment Snapshot
- P/B of 0.17 — trading below book value
- Low leverage — D/E ratio of 0.04
- Loss-making — negative ROE of -415.6%
Propanc Biopharma, Inc. - Common Stock (PPCB) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $3 million . Key value metrics: P/B ratio 0.17.
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Propanc Biopharma, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, PPCB shows negative return on equity of -415.6% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.04.
StockPik's composite Value Score for PPCB is 70/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.